<DOC>
	<DOCNO>NCT02633111</DOCNO>
	<brief_summary>The purpose study determine whether blood test accurately detect whether participant 's lymphoma come back completion initial chemotherapy treatment aggressive B-cell Non-Hodgkin lymphoma . The purpose study see MRD blood sample potentially replace CT scan completion chemotherapy future .</brief_summary>
	<brief_title>DNA Sequencing-Based Monitoring Minimal Residual Disease Predict Clinical Relapse Aggressive B-cell Non-Hodgkin Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<criteria>18 year age time sign informed consent Histologyconfirmed aggressive Bcell NonHodgkin lymphoma De novo diffuse large Bcell lymphoma ( include subtypes primary mediastinal Bcell lymphoma Tcell rich Bcell lymphoma ) . According 2008 WHO Classification Hematopoietic Lymphoid Tumors . These would include double triplehit diffuse large Bcell lymphoma MYC/BCL2 and/or BCL6 gene rearrangement . These case may classify high grade Bcell lymphomas accord 2017 revision WHO Classification Hematopoietic Lymphoid Tumors . Recipient frontline multiagent chemotherapy ( example , RCHOP , dose adjustedREPOCH , RCHOP/RICE , RCHOP+investigational agent , etc ) . Eligible patient recently receive ( â‰¤ 4 month end treatment assessment ) , actively receive , plan receive frontline chemotherapy near future ( within 3 month sign consent ) . A frontline therapy program include different sequential phase treatment , include highdose therapy autologous stem cell transplantation . Required pretreatment test specimen bone marrow , blood , lymph node , alternate site identify tumorspecific clonotype . Ability adhere study visit schedule protocol requirement , include surveillance imaging MRD test specimen collection specify time point . Patients receive 2nd great line therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>DNA Sequencing</keyword>
	<keyword>15-180</keyword>
</DOC>